Madrigal Pharmaceuticals
MDGL
75 hedge funds and large institutions have $16.3M invested in Madrigal Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 18 reducing their positions, and 22 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 18
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 84 → 75 (-9)
39% less call options, than puts
Call options by funds: $79K | Put options by funds: $130K
41% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 22
86% less capital invested
Capital invested by funds: $119M → $16.3M (-$103M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.96M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$953K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$776K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$694K |
| 5 |
Goldman Sachs
New York
|
+$633K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$12.1M |
| 2 |
Jennison Associates
New York
|
-$11.5M |
| 3 |
AC
Armistice Capital
New York
|
-$3.48M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.57M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.46M |
MDGL Hedge Fund Activity: Q4 2015 in Review
75 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q4 2015, worth a combined $16.3M — down 86% from $119M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of MDGL and 13 opened new positions — a net loss of 9 holders — while 18 trimmed existing stakes and 26 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.96M. The largest seller was Caxton Corporation, cutting an estimated $12.1M.
- 75 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q4 2015, down from 84 in Q3 2015.
- Funds reported $16.3M of Madrigal Pharmaceuticals stock for Q4 2015, down 86% quarter-over-quarter.
- 13 funds opened new Madrigal Pharmaceuticals positions in Q4 2015 and 22 closed out, a net change of -9 holders.
- The largest Madrigal Pharmaceuticals buyer in Q4 2015 was Renaissance Technologies, an estimated $1.96M added.
- The largest Madrigal Pharmaceuticals seller in Q4 2015 was Caxton Corporation, an estimated $12.1M sold.
Based on aggregated 13F filings for Q4 2015.